Jan Pruim

List of Publications by Year
in descending order

34 papers	2,429 citations	471061 17 h-index	454577 30 g-index
35 all docs	35 docs citations	35 times ranked	3010 citing authors

#	Article	IF	Citations
1	FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 181-200.	3.3	1,147
2	The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 2320-2333.	3.3	343
3	Detection of unknown occult primary tumors using positron emission tomography. , 1998, 82, 1160-1166.		204
4	Screening for distant metastases in head and neck cancer patients by chest CT or whole body FDG-PET: A prospective multicenter trial. Radiotherapy and Oncology, 2008, 87, 221-229.	0.3	97
5	A systematic review on the role of FDG-PET/CT in tumour delineation and radiotherapy planning in patients with esophageal cancer. Radiotherapy and Oncology, 2010, 97, 165-171.	0.3	78
6	Dynamics of tumor hypoxia assessed by 18F-FAZA PET/CT in head and neck and lung cancer patients during chemoradiation: Possible implications for radiotherapy treatment planning strategies. Radiotherapy and Oncology, 2014, 113, 198-203.	0.3	66
7	Consequences of additional use of PET information for target volume delineation and radiotherapy dose distribution for esophageal cancer. Radiotherapy and Oncology, 2009, 93, 447-453.	0.3	64
8	FDG-PET and detection of distant metastases and simultaneous tumors in head and neck squamous cell carcinoma: A comparison with chest radiography and chest CT. Oral Oncology, 2009, 45, 234-240.	0.8	58
9	18F-DCFPyL PET/CT in the Detection of Prostate Cancer at 60 and 120 Minutes: Detection Rate, Image Quality, Activity Kinetics, and Biodistribution. Journal of Nuclear Medicine, 2017, 58, 1797-1804.	2.8	50
10	Head and Neck Tumor Hypoxia Imaging by 18F-Fluoroazomycin-arabinoside (18F-FAZA)-PET. Clinical Nuclear Medicine, 2014, 39, 44-48.	0.7	48
11	Carbon-11 choline or FDG-PET for staging of oesophageal cancer?. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 1845-1849.	3.3	44
12	Application of artificial intelligence in nuclear medicine and molecular imaging: a review of current status and future perspectives for clinical translation. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 4452-4463.	3.3	29
13	99mTc-HDP bone scintigraphy and 18F-sodiumfluoride PET/CT in primary staging of patients with prostate cancer. World Journal of Urology, 2018, 36, 27-34.	1.2	25
14	Serial FLT PET imaging to discriminate between true progression and pseudoprogression in patients with newly diagnosed glioblastoma: a long-term follow-up study. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2404-2412.	3.3	21
15	Oesophageal tumour progression between the diagnostic 18F-FDG-PET and the 18F-FDG-PET for radiotherapy treatment planning. Radiotherapy and Oncology, 2013, 106, 283-287.	0.3	20
16	Effectiveness of an 18F-FDG-PET based strategy to optimize the diagnostic trajectory of suspected recurrent laryngeal carcinoma after radiotherapy: The RELAPS multicenter randomized trial. Radiotherapy and Oncology, 2016, 118, 251-256.	0.3	20
17	First Clinical Results of (d)-¹⁸F-Fluoromethyltyrosine (BAY 86-9596) PET/CT in Patients with Nonâ€“Small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma. Journal of Nuclear Medicine, 2014, 55, 1778-1785.	2.8	19
18	Clinical validation of FDG-PET/CT in the radiation treatment planning for patients with oesophageal cancer. Radiotherapy and Oncology, 2014, 113, 188-192.	0.3	18

#	Article	IF	Citations
19	Carbon-11 tyrosine PET for visualization and protein synthesis rate assessment of laryngeal and hypopharyngeal carcinomas. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 1182-1187.	3.3	13
20	Total Body Metabolic Tumor Response in ALK Positive Non-Small Cell Lung Cancer Patients Treated with ALK Inhibition. PLoS ONE, 2016, 11, e0149955.	1.1	11
21	An exploratory study of volumetric analysis for assessing tumor response with 18F-FAZA PET/CT in patients with advanced non-small-cell lung cancer (NSCLC). EJNMMI Research, 2016, 6, 33.	1.1	11
22	Assessment of hypoxic subvolumes in laryngeal cancer with 18F-fluoroazomycinarabinoside (18F-FAZA)-PET/CT scanning and immunohistochemistry. Radiotherapy and Oncology, 2015, 117, 106-112.	0.3	10
23	Alternative PET tracers in head and neck cancer. A review. European Archives of Oto-Rhino-Laryngology, 2013, 270, 2595-2601.	0.8	7
24	Evaluation of elastix-based propagated align algorithm for VOI- and voxel-based analysis of longitudinal 18F-FDG PET/CT data from patients with non-small cell lung cancer (NSCLC). EJNMMI Research, 2015, 5, 15.	1.1	7
25	Is Câ€11 Methionine PET an alternative to 18â€F FDGâ€PET for identifying recurrent laryngeal cancer after radiotherapy?. Clinical Otolaryngology, 2019, 44, 124-130.	0.6	6
26	Impact of fasting on 18F-fluorocholine gastrointestinal uptake and detection of lymph node metastases in patients with prostate cancer. EJNMMI Research, 2016, 6, 2.	1.1	3
27	Prediction of survival and therapy outcome with 11C-tyrosine PET in patients with laryngeal carcinoma. Journal of Nuclear Medicine, 2004, 45, 2052-7.	2.8	3
28	Prospective analysis of serial FLT-PET scanning to discriminate between true and pseudoprogression in glioblastoma.. Journal of Clinical Oncology, 2014, 32, 2009-2009.	0.8	2
29	Blinded Mid-Treatment FDG-PET in Newly Diagnosed Aggressive Non-Hodgkin Lymphoma (NHL): First Results of a Prospective Multicenter Study.. Blood, 2006, 108, 2400-2400.	0.6	1
30	Total body metabolic tumor response in ALK-positive non-small cell lung cancer treated with crizotinib.. Journal of Clinical Oncology, 2014, 32, e19062-e19062.	0.8	1
31	PTLD Visualization by FDG-PET: Improved Detection of Extranodal Localizations and Response Monitoring.. Blood, 2005, 106, 5389-5389.	0.6	0
32	Prognostic impact of hexokinase and glucose transporter expressions and clinicopathologic features related to F-18-FDG uptake in esophageal cancer.. Journal of Clinical Oncology, 2012, 30, 39-39.	0.8	0
33	11C-choline PET/CT in selection of patients for salvage cryoablation in recurrent prostate cancer.. Journal of Clinical Oncology, 2013, 31, 188-188.	0.8	0
34	Clinical impact of 11C-Choline PET/CT in selection and outcome of salvage cryoablation in patients with recurrent prostate cancer after radiotherapy.. Journal of Clinical Oncology, 2016, 34, 276-276.	0.8	0